Skip to Content

Ixifi FDA Approval History

FDA Approved: Yes (First approved December 13, 2017)
Brand name: Ixifi
Generic name: infliximab-qbtx
Dosage form: Injection
Company: Pfizer Inc.
Treatment for: Crohn's Disease, Maintenance, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis

Ixifi (infliximab-qbtx) is a tumor necrosis factor (TNF) blocker biosimilar to Remicade (infliximab) indicated for the treatment of Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

Development Timeline for Ixifi

DateArticle
Dec 13, 2017ApprovalFDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.